Introducing The Next Generation ofContinuous Glucose Monitoring
The GlySens Eclipse 3 nothing attached to the body - lasts for years
Nothing on the Body
Unlike existing CGM devices that must be adhered to the skin, the GlySens Eclipse 3 CGM is fully implantable. There is nothing visible on the body
Long-Term Duration
Device life is measuring in years - not days. The Eclipse 3 is capable of running for more than 2 years without needing replacement
Entirely Continuous
The Eclipse 3 is always measuring and transmitting glucose readings to the user's phone
Fully Interoperable
The implant has on-board Bluetooth for seamless connectivity to insulin pumps, smart pens, and other connected health applications
Built withInnovative Technology Based on Strong Science
Developed over many years, the Eclipse 3 sensor employs a number of unique and groundbreaking technologies to ensure a long lasting and accurate device
Unique Sensing Engine
GlySens uses a fundamentally different approach to measure glucose
Oxygen Based Glucose Sensing Unlike conventional CGMs, GlySens technology relies on measuring oxygen rather than hydrogen peroxide as a signal for glucose. This difference allows the sensor to be protected from the tissue environment, enabling the sensing engine to run for years rather than days and be insensitive to interferents.
Multi-Channel Array Rather than a single point measurement of glucose, the Eclipse 3 utilizes a redundant array of detectors to ensure a highly accurate measurement resistant to artifacts and noise.
3 Electrode Electrochemical Cell GlySens employs a stable 3-electrode cell rather than the widely used and quick to degrade 2-electrode system allowing the implant to run for extremely long durations.
Designed for Long Term Use
GlySens has developed and implemented a number of innovative solutions allowing the implant to operate for durations measured in years rather than days.
Anti-Inflammatory Drug Elution An anti-inflammatory drug eluting membrane integrated onto the implant ensures a healthy tissue environment for the life of the device. This allows the implant to accurately measure glucose in the face of the body's foreign body response.
Stabilized Enzymes State of the art immobilization methods have been implemented allowing the enzymes needed for sensing to remain active for periods unheard of in other devices and applications.
Easily Replaceable When it's time for a replacement, a new sensor can be implanted into the same tissue space formed by the first device making the whole process quick and easy.
Fully Integrated
No need for any body-worn components. Everything needed to measure and report glucose is built into the implant itself.
Integrated Power Implant grade high density battery integrated into the implant allows for continuous operation for over two years without recharging or replacement.
Direct Connectivity Bluetooth Low Energy built into the implant allows it to connect directly to devices outside the body, be it a phone or a watch or an insulin pump, enabling Automated Insulin Delivery and communication with other connected health applications through secure protocols.
Embedded Algorithms All glucose calculation algorithms run on the implant's embedded microprocessor allowing the device to transmit a glucose measurement via Bluetooth without any processing needing to occur elsewhere.
Based on a Strong History of Development
43
Granted and Pending Patents
7
Human Clinical Trials Completed
Led by a Talented andExperienced Team
The chief leaders at GlySens are renowned professionals with deep experience in the medical device field. They lead an accomplished and dedicated team of R&D, operational, quality, marketing and regulatory professionals. Our medical and business advisory group is comprised of highly experienced clinicians, corporate, financial, legal and IP resource experts.
Executive Management
William H. Markle
President & CEO
William (Bill) Markle is President and CEO of GlySens. Mr. Markle has a 30-year track record of successful product and global market development, clinical evaluation, and visionary leadership in the medical device field. He was formerly founder, President, and CEO of GluMetrics, Inc. At GluMetrics, he directed the successful development of continuous real-time sensing technology for intravascular glucose monitoring in the intensive care and operating room environment. Previously, he held senior executive positions in marketing and business development at Tensys Medical and Masimo Corporation, and related positions at Baxter Edwards Critical Care and American Hospital Supply. Mr. Markle is an MBA graduate of Pepperdine University and an engineering graduate of Duke University. He is a named inventor on numerous issued U.S. patents and published applications.
Dr. Bruce Buckingham received his medical degree from University of California at San Diego. He completed his internship, residency, and fellowship at Children’s Hospital of Los Angeles. He is currently a Professor in the Department of Pediatric Endocrinology at Stanford Medical Center and the Stanford Children’s Hospital. His research focuses on continuous glucose monitoring in children and closed-loop (artificial pancreas) systems. He has collaborated on various overnight and 24-hour closed-loop platforms in development and has helped to develop algorithms for detecting infusion set and sensor failures and to improve infusion set wear duration. Dr. Buckingham is well recognized as a leading expert in the real-world application and clinical use of continuous glucose monitoring systems.
Daniel Einhorn, MD
Dr. Daniel Einhorn is medical director of the Scripps Whittier Diabetes Institute, clinical professor of medicine (voluntary) at UC San Diego, president of Diabetes and Endocrine Associates, and associate editor of the Journal of Diabetes. He is a trustee and past-president of the American College of Endocrinology (ACE), a founding member and regent of the ACE Foundation, and past-president of the American Association of Clinical Endocrinologists (AACE). He received his BA at Yale (Summa cum Laude), his MD at Tufts (AOA) and his post-graduate training at Harvard. He has been in a leadership position in endocrinology for over 20 years during which time he has had the privilege of co-writing many national guidelines, including those for diabetes, pre-diabetes, inpatient diabetes management, and obesity, as well as leading consensus conferences on insulin resistance, pre-diabetes, obesity, and glucose monitoring. He has won the highest awards from AACE, ACE, and the Endocrine Society as well as numerous other honors. He has been on hundreds of teaching programs, written dozens of papers and chapters on diabetes, served on many dozens of scientific advisory committees, and has participated in clinical research on virtually all classes of diabetes therapies and diagnostics. He continues to be a practicing physician who loves seeing patients and their families and who appreciates the real world education he gets from them every day.
Board of Directors
Daniel P. Connally, CFA, Principal, Fayez Sarofim & Co.
Robert L. Engler, MD, Professor of Medicine, Emeritus, University of California, San Diego
Adam E. Fine, MBA, Founder and Managing Partner, Windham Venture Partners
Orville G. Kolterman, MD, Clinical & Regulatory Expert, former CMO, Amylin Pharmaceuticals, Inc.
William H. Markle, President and CEO, GlySens Incorporated
R. Cary McNair, Chairman and CEO, McNair Interests
Richard P. Thompson, Diabetes Entrepreneur and past President and CEO of ReShape Medical, Inc.
Contact Us
GlySens Incorporated Corporate Headquarters 3931 Sorrento Valley Blvd. Suite 110 San Diego, California 92121 +1 (858) 638-7708
Want to learn more? Please send us an email or call our office, we would love to hear from you.
CAUTION - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.
The Eclipse 3 System is currently under development and is not yet approved, cleared, or otherwise available for commercial or public distribution. The system is currently undergoing clinical evaluation; initial human implant trials have been completed and preparations for additional human trials are underway.
Sign up to stay informed on the latest from GlySens
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
